Fumonisin B r is associated with various animal and human carcinomas and toxicoses, including leukoencelphalomalacia, hepatocarcinoma, pulmonary edema and esophageal carcinoma. We have examined the cellular effects of fumonisin Bj in vitro using cellular model systems relevant to potential human target tissues. Although fumonisin B, has been described as a mitogen in Swiss 3T3 cells based on stimulation of [ 
Introduction
Fungi of the genus Fusarium produce a spectrum of mycotoxins, including fumonisin B). Exposure to fumonisin B] through dietary consumption of Fw^anMrn-contaminated corn products has been linked epidemiologically to increased rates of human esophageal cancer in the Transkei region of South Africa and in the Linxian province of the Peoples Republic of China (1). Fumonisin B| has also been associated etiologically with several animal toxicoses, including equine leukoencephalomalacia and porcine pulmonary edema (2) (3) (4) .
Previous studies have characterized fumonisin B] as both a tumor initiator (5) and a tumor promoter in rodents (6) and as a mitogen based on its ability to stimulate [ 3 H]thymidine incorporation in Swiss 3T3 murine fibroblasts (7) . However, other studies have demonstrated that fumonisin Bj is not a mutagen in Salmonella mutagenicity assays (8) and does not induce unscheduled DNA synthesis in rat primary hepatocytes in culture (9) . These results indicate that fumonisin B] is not a genotoxic tumor initiator. Furthermore, fumonisin B[ decreases [
3 H]thymidine incorporation by rat hepatocytes stimulated to proliferate by partial hepatectomy (10). Therefore, the precise role of fumonisin B| in carcinogenesis is not well denned.
The effects of fumonisin B i have not been examined using human cell types related to suspected fumonisin B) target tissues in humans, namely esophagus and liver. Therefore, we utilized four cell types in this study to examine the cellular effects of fumonisin B, in vitro. Normal human keratinocytes and fibroblasts isolated from neonatal foreskins were selected for these studies because they represent a readily available and renewable source of untransformed human cells that model the epithelium and lamina propria of the esophagus. In addition, HET-IA, an SV-40 T-antigen-immortalized human esophageal epithelial cell line (11) , was also exploited to evaluate the effects of fumonisin Bj on initiated esophageal cells. Finally, the effect of fumonisin B| on HepG2 human hepatocarcinoma cells was evaluated, since it is a human liver cancer cell line that has retained many functions associated with fully differentiated primary hepatocytes (12) (13) (14) (15) (16) (17) .
The effects of fumonisin B] on the growth potential of these model cell types was evaluated by clonal growth analysis, incorporation of [ 3 H]thymidine and changes in absolute cell number. We further characterized the effects of fumonisin B! on human keratinocytes by DNA fragmentation analysis, clonogenicity, cell viability analysis, cell cycle distribution, chromatin staining and morphology.
Materials and methods

Chemicals and biochemicals
Fumonisin B| was isolated as the free acid from F.proliferatum cultures as described previously (18) . The purity of the isolated fumonisin B| was determined by HPLC, MS and NMR techniques to be 92.5% (19, 20) . Thapsigargin was obtained from Calbiochem (La Jolla, CA). [5,6- 
W.H.Tolleson et al Cells and cell culture conditions
Neonatal human keratinocytes (NHKc*) were isolated from human foreskin specimens by the overnight trypsin flotation technique (21) and were maintained in culture with recombinant human epidermal growth factor and bovine pituitary extract-supplemented Keratinocyte SFM (KSFM + +) medium (Gibco, Grand Island, NY). Some keratinocyte treatments occurred in Keratinocyte SFM without added epidermal growth factor or bovine pituitary extract (KSFM= medium). Human fibroblasts (HFb) were isolated from human foreskin specimens by overnight digestion at 37°C in 1% collagenase (Sigma, St Louis, MO) in 3:1 Dulbecco's phosphate-buffered saline (D-PBS)/minimum essential medium (MEM; Gibco) as described by Pirisi et al. (21) and were maintained in MEM supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco), 200 U/ml penicillin, and 200 mg/ml streptomycin sulfate. Swiss 3T3 cells were obtained from the American Type Culture Collection (Rockville, MD) and maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco) supplemented with 10% FBS, 200 U/ml penicillin and 200 mg/ml streptomycin sulfate. HET-1A cells were obtained at passage 31 from G.D.Stoner (Ohio State University) and maintained in EPM-2 medium (BRFF, Ijamsville, MD) (11, 22, 23) . The human hepatocellular carcinoma cell line HepG2 was obtained from the American Type Culture Collection and cultured in Eagle's minimum essential medium (Biowhittaker, Walkersville, MD) supplemented with 10% heat-inactivated FBS, 2.0 mM L-glutamine, 200 U/ml penicillin and 200 mg/ml streptomycin sulfate (Hep medium) (15) . All cultures were maintained in a 5% CO 2 humidified incubator at 37°C.
Cellular proliferation assays
Keratinocyte proliferation was determined by clonal growth assay as described by Pinsi et al. (24) . NHKc were plated at low density (30 cells/cm 2 ) in triplicate 60 mm dishes in 5 ml KSFM+ + . HET-1A cells were similarly plated in 5 ml EPM2/60 mm dish. The cells were allowed to attach overnight, then the medium was changed to the experimental conditions given in the figure legends. The colonies were allowed to expand clonally for 4-8 days in the presence or absence of fumonisin Bj, with the medium being changed once at the exposure mid-point. The cells were washed three times with D-PBS and fixed with methanol. The fixed cells were stained with Giemsa stain, rinsed with water and the surface area covered by colonies was determined by video image analysis (Optimus, Bioscan Inc., Edmonds, WA) and normalized to the untreated controls. Fibroblasts (5000 HFb/100 mm dish) were plated in 10 ml MEM with 10% FBS. The cells were maintained under the experimental conditions for 4 days, the medium was changed after 2 days and the total number of cells per dish was quantified using an automatic cell counter (Coulter model ZF, Hialeah, FL).
[ 3 H]Thymidine incorporation was also used to evaluate proliferation. Because of variable growth properties and fumonisin B! sensitivities, the optimal dose and time dependencies of each cell type in this assay were determined in preliminary experiments. Subsequently NHKc, HepG2 or Swiss 3T3 cells were plated in appropriate media on triplicate 60 mm dishes. The cells were provided medium containing various levels of fumonisin B, for the times specified (see Table I legend), after which 5 mCi/dish [5, H]thymidine was added for up to 8 h. The medium was then removed, the cells were washed three times with D-PBS, fixed with 10% trichloroacetic acid (TCA) for 15 min at 0°C, rinsed three times with 10% TCA at 0°C and resolubilized in two 0.1 ml portions of 0.2 M NaOH. The TCA-precipitable radioactivity was determined by liquid scintillation counting with 20 ml Ecolite+ (ICN).
Clonogenicity assay
NHKc in triplicate 150 mm dishes were exposed to 0-10"" 4 M fumonisin B, for up to 6 days in KSFM= medium. At the end of the exposure period the cells were washed three times with D-PBS, trypsinized, resuspended in 10 ml KSFM++ and counted in a hemacytomer. Cells from each group were replated in tnplicate 100 mm dishes (5000 cells/dish) with 10 ml KSFM + +/ dish and refed every 2 days. On the sixth day after replating, the cells were washed with D-PBS, fixed with methanol, stained with Giemsa and the colonies per dish determined.
Cell cycle analysis
NHKc were plated in four 150 mm tissue culture dishes (2.2X10* cells in 20 ml KSFM + +/dish) and allowed to attach ovemighL The medium in two dishes was then switched to 25 ml KSFM= and the medium in the remaining dishes was switched to KSFM= containing 10~5 M fumonisin B|. After 40 h exposure, 10~3 M bromodeoxyuridine (BrdU) was added to one dish from each pair and incubated for 1 h at 37°C. The cells in all four dishes were washed with D-PBS, harvested by trypsinization, pooled with any potential floating cells from the original conditioned medium and repelleted.
Cells were prepared for BrdU detection according to the supplier's protocol (Becton-Dickinson, Mountain View, CA). Briefly, the cells were gently resuspended in 1 ml normal saline for 10 min at 0°C, fixed with 10 ml ice- green) fluorescence signal was measured using logarithmic amplification (4 decade log scale). The data were collected (25 000 events/sample) in list mode using the LYSIS II software system (Becton-Dickinson) and further processed using the WinMDI software package (J.Trotter, Salk Institute, La Jolla, CA).
Cellular viability analysis
The ability of cells treated with fumonisin B| to exclude propidium iodide, a cell impermeable nuclear stain, and to de-esterify fluorescein diacetate was used as a measure of cellular viability (25) (26) (27) . NHKc were cultured in the presence or absence of fumonisin B| or thapsigargin, harvested by trypsinization and 10* cells pelleted and resuspended in 5 ml D-PBS. Fluorescein diacetate (10 ng/ml; Molecular Probes, Eugene, OR) and propidium iodide (10 mg/ml) were added and the mixture incubated for 10 min at 37°C, pelleted, washed with D-PBS and resuspended in 0.8 ml D-PBS. The cells were then subjected to flow cytometric analysis (25 000 events/sample) as described above, except that the flow rates were 200-450 particles/s and the propidium iodide-dependent fluorescence signal (FL-2, red) was collected with logarithmic amplification (4 decade log scale).
FAC sorting and transmission electron microscopy
NHKc were plated (3X10 6 cells in 25 ml KSFM + +/150 mm dish) and allowed to attach overnight. The medium was changed to KSFM= containing 10" 4 M fumonisin B| and the cells were refed every 2 days. The cells were stained by the propidium iodide/fluorescein diacetate cell viability method described above and electronically sorted using a FACStar Plus (BectonDickinson) flow cytometer with an Inova 70 argon ion laser (Coherent, San Jose, CA) tuned to the 488 nm line at 200 mW. Both FL-1 (green, fluorescein) and FL-2 (red, propidium iodide, BP640 ft 10 nm) fluorescence were measured with logarithmic amplification (4 decade log scale) triggering on the FSC signal. Sterile 1X phosphate-buffered saline was used as the sheathing fluid and the sort rate was 2.5-3.0X10 3 cells/s. LYSIS-II (Becton-Dickinson) software was used to establish the sort regions. The stained keratinocytes were sorted into 5.0 ml sterile tubes (Falcon, Franklin Lakes, NJ), maintained on ice after sorting until centrifugation and then fixed in 4% glutaraldehyde for electron microscopy. The fixed cells collected from each sort region were embedded in epoxy resin, 0.9 mm sections were prepared and examined by transmission electron microscopy.
Morphological observations
NHKc were cultured in 100 mm tissue culture dishes in the presence or absence of 10"" 4 M fumonisin Bi in KSFM= for 5 days and phase contrast photomicrographs were prepared. NHKc were cultured on tissue culture grade 22 mm plastic coverslips in 35 mm wells under the conditions given in the text, washed with D-PBS, fixed with 10% neutral buffered formalin and stained with 5 ng/ml acridine orange.
In situ end-labeling immunocytochemistry NHKc (10 3 cells/dish) were plated on poly-L-lysine-coated microscope slides in 100 mm dishes in 10 ml KSFM + + , allowed to attach overnight and the medium changed to KSFM= containing 0-10" 4 M fumonisin B|. The cells were refed as above after 2 days of treatment. After a total of 4 days exposure the cells were washed with D-PBS, fixed with 10% neutral buffered formalin and rerinsed with D-PBS. Cells with DNA strand breaks were detected by in situ end-labeling immunocytochemistry using the ApopTag™ peroxidase labeling kit (Oncor, Gaithersburg, MD) according to the supplier's protocol. Briefly, the terminal 3'-hydroxyl groups occurring at DNA strand breaks were enzymatically extended with 5-digoxigeninyl-2'-deoxyuridylate (dig-dUrd) using terminal deoxynucleotidyltransferase. These digoxigenin-labeled strand breaks were immunochemically revealed using a horseradish peroxidaseconjugated anti-dig-dUrd antibody with a diaminobenzidine/hydrogen peroxide substrate mixture. The cells were lightly counterstained with hematoxylin. Total cell number and immunocytochemically labeled cells were determined using bright field microscopy.
DNA fragmentation analysis
NHKc were plated (8X lO^lOO mm dish) with 10 ml KSFM + + and allowed to attach for 6 h. The medium was switched to 10 ml KSFM= with 0 or 10" 4 M fumonisin By and cultured for 1-4 days, refeeding daily. Conditioned medium was collected at 24 h intervals and the attached cells rinsed with 5 ml D-PBS. The D-PBS wash was added to the collected medium, cellular debris was removed by centrifugation at 500 g for 5 min and the nucleic acids remaining in the supernatant were recovered by ethanol precipitation. The nucleic acid pellets were rinsed with 70% ethanol, dissolved in 10 mM Tris, 1 mM EDTA, pH 8 (TE buffer), digested with RNase A (350 mg/ml) for 2 h, proteinase K (350 mg/ml) for 1.5 h, extracted with phenol/chloroform (1:1) and reprecipitated with ethanol. The ethanol precipitates were redissolved in TE buffer and subjected to electrophoresis through 2.0% agarose gels in the presence of 0.5 ng/ml ethidium bromide.
Results
Fumonisin Bj inhibits proliferation of human keratinocytes, fibroblasts, HET-1A and HepG2 cells, but stimulates [ 3 H]-thymidine incorporation into Swiss 3T3 cells
The influence of fumonisin B, on human keratinocyte cellular proliferation was evaluated by its effect on the expansion of NHKc colonies. The results from clonal growth assays using NHKc from three different individuals are shown in Figure  1A , where 10" 5 M fumonisin B[ inhibited NHKc expansion by 50% (IC50). Human keratinocytes were additionally exposed to 0-10" 4 M fumonisin B] in the presence of added growth factors (bovine pituitary extract and recombinant human epidermal growth factor) for 6 days ( Figure IB) . It is apparent that inhibition of keratinocyte clonal expansion by fumonisin Bi (IC50 10~5 M) is independent of the presence of these exogenous growth factors.
Increased [ 3 H]thymidine incorporation into Swiss 3T3 murine fibroblasts exposed to 10~* M fumonisin B| has been reported previously (7) . We also observed fumonisin B r dependent stimulation of [ (Table I) . This level of fumonisin B| was below the minimum concentration 
Fumonisin B/ decreases the clonogenicity of human keratinocytes
The clonogenicity of NHKc, which refers to their ability to form proliferating colonies when replated, decreased to 44.5% of control levels after 2 days exposure to 10" 4 M fumonisin B] and was virtually eliminated after 4 days exposure ( Figure  2 ). The clonogenicity of the control cells was expected to be low after being maintained in KSFM= medium, due to the lack of growth factors believed to be important for maintaining NHKc cell replating competence. However, since all of the cells were replated in KSFM++ growth factor complete NHKc were exposed to 0 or 10" 4 M fumonisin B| for 0-6 days, then replated in triplicate 100 mm dishes and allowed to expand clonally. The colonies were fixed, stained and counted after 6 days of culture in KSFM + + (empty circles, no fumonisin B|j filled circles, 10"** M fumonisin B,).
medium, reasonable replating efficiencies were observed (8.0% replating efficiency in these KSFM= controls versus 50% replating efficiency for NHKc maintained in KSFM++).
Anti-proliferative effects of fumonisin Bj are not due to cell cycle arrest
The effect of fumonisin B, on the distribution of NHKc in the various phases of the cell cycle was investigated by bivariate DNA analysis ( Figure 3A-C) . The thymidine analog BrdU is incorporated into newly synthesized DNA of cells in the S phase of the cell cycle. These cells can be identified using a FTTC-labeled anti-BrdU monoclonal antibody. The relative DNA content of all of the cells was measured using propidium iodide staining. Cells in Gt/G] will exhibit a fluorescence signal proportional to a 2-fold relative DNA content, whereas those in G 2 /M will display a propidium iodide-dependent fluorescence proportional to a 4-fold relative DNA content. Thus cells in the various phases of the cell cycle can be discriminated by bivariate DNA analysis using flow cytometry. Exposure of NHKc to 10~5 M fumonisin B, for 40 h did not alter the distribution of cells in the various phases of the cell cycle ( Figure 3C ). In addition, we did not observe a subdiploid population such as those reported for apoptotic cells in some other systems.
Fumonisin B t decreases the viability of keratinocytes
The expression of cellular (non-specific) esterase activity is an indicator that normal cellular metabolic functions are active in viable cells (26, 27) . Viable cells should be capable of deacylating the non-fluorescent, cell-permeable fluorescein diacetate dye to the fluorescent, cell-impermeant fluorescein free acid form and thus be strongly fluorescent in the FL1 channel by flow cytometry. Cells with intact membranes (e.g. viable and early apoptotic cells) exclude propidium iodide, preventing its intercalation into intracellular nucleic acids. Thus these cells do not exhibit enhanced DNA-dependent fluorescence due to propidium iodide-DNA complex formation, which would be detected in the FL2 (propidium iodide, red) channel of the flow cytometer. Necrotic cells lack esterase activity necessary for fluorescein diacetate hydrolysis and are incapable of retaining free fluorescein due to compromised membrane integrity. Furthermore, necrotic cells should be thoroughly labeled with propidium iodide, since their damaged membranes should be incapable of excluding the stain. Thus necrotic cells should exhibit very strong propidium iodide fluorescence (FL2) and very weak fluorescein (FL1) fluorescence.
Apoptotic cells would be expected to have less esterase activity than viable cells, depending on the half-lives of the esterases relative to the overall rate of apoptosis. Apoptotic cells also retain their membrane integrity and thus exclude propidium iodide. Because NHKc are not phagocytically competent and also adhere strongly to tissue culture dishes, the carcasses of NHKc dying apoptotically in culture remain attached to the solid substrate. Therefore, at the terminal stage of apoptosis of cultured NHKc (referred to here as secondary necrosis) the capacity to exclude propidium iodide will be lost, along with residual esterase activity. Also, the degree of fluorescein accumulation observed in NHKc in the earlier stages of apoptosis may vary if membrane repair functions are lost prior to the loss of esterase activity. In the latter case cells in the early stages of apoptosis would be expected to exhibit propidium iodide and fluorescein diacetate staining properties similar to viable cells (e.g. fluorescein-positive and propidium iodide-negative), while NHKc in the final stages of apoptosis in which their membrane integrity was compromised due to secondary necrosis would appear more like necrotic cells (e.g. fluorescein-negative, propidium iodide-positive).
Thapsigargin, a non-12-0-tetradecanoylphorbol-13-acetate (TPA)-type tumor promoter, induces apoptosis through inhibition of the calcium-dependent ATPase of the endoplasmic reticulum and subsequent accumulation of excess intracellular calcium (29) (30) (31) ). An increased number of propidium iodidepositive, fluorescein-negative cells was noted in NHKc in response to exposure to ICH-IO" 4 M fumonisin B, or 5.0X 10^ M thapsigargin for 6 days ( Figure 4A-C) . The fluoresceinnegative, propidium iodide-positive region appears to be composed of two sub-populations differing in their intensities of DNA-dependent propidium iodide fluorescence (FL-2). We observed that the non-viable sub-population with lower propidium iodide fluorescence increased more dramatically relative to controls ( Figure 4A and B) and maximized at 4 days exposure to 10" 4 M fumonisin B| ( Figure 4D ).
Similarly, we noted that the propidium iodide-positive, Figure 6C ). The identification of terminally differentiating NHKc in the presence of apoptotic cells was based on the abundance of keratin tonofilaments in conjunction with cellular dimensions and cytoplasmic and chromatin condensation (i.e. larger cells with abundant tonofilaments but showing chromatin margination, increased vacuolization and less condensed cytoplasm were considered terminally differentiated, smaller cells with condensed cytoplasm and fewer tonofilaments and some chromatin margination were considered early apoptotic).
The fluorescein-negative, propidium iodide-positive subpopulations included necrotic cells ( Figure 6D , indicated by cellular swelling, loss of membrane integrity and damaged organelles), along with cells in the later phases of apoptosis ( Figure 6E , indicated by chromatin condensation at the nuclear periphery, nuclear fragmentation, membrane blebbing, intact organelles and cytoplasmic condensation). Unfortunately, the FACS technique was unable to discriminate between these two sub-populations definitively. Thus we characterized the cells in these regions as non-viable.
Alterations in morphology, nuclear staining and in situ immunocytochemical end-labeling resulting from exposure to fumonisin B t Keratinocytes exposed to fumonisin B ( for 1-3 days did not exhibit gross morphological changes in shape or size (data not shown). However, after day 4 of exposure to fumonisin B, in culture NHKc adopted a spherical, swollen morphology ( Figure  7A and B). When fumonisin B r treated, formalin-fixed NHKc are stained with 5 |ig/ml acridine orange the swollen cells exhibited highly fluorescent and pyknotic nuclei, consistent with margination of chromatin at the nuclear periphery ( Figure  1C and D) .
The effects of various doses of fumonisin B| on DNA fragmentation in situ were also examined in NHKc by in situ immunocytochemical end-labeling of the 3'-hydroxyl groups of fragmented DNA using the ApopTag™ kit ( Figure 7E and F and Table II ). NHKc exposed to 10^ M fumonisin B, for 4 days showed a 7.7-fold increase in nuclear labeling relative to untreated controls (27.7 versus 3.6% cells labeled respectively). It has been reported that DNA strand breaks generated during necrosis or DNA replication can be in situ end-labeled in some cell types. However, the staining resulting from these processes is typically less intense than that resulting from the extensive DNA fragmentation occurring during the process of apoptosis (32) . Only cells that were labeled very intensely by in situ end-labeling and exhibited morphological features consistent with NHKc apoptosis were scored as positive in this analysis.
A fraction (3.6%) of the control cells were also labeled by the in situ end-labeling technique (Table II) . This is not unexpected, considering that the keratinocytes used in these experiments include cells at various stages of the processes of *NHKc were plated on poly-L-lysine-coated glass microscope slides, exposed to 0-10" 4 M fumonisin B| for 5 days, fixed, processed using an ApopTag™ kit and counterstained with hematoxylin. All cells in a 0.8 mm wide path across the slide were examined.
exposure to ]S 100 uM fumonisin Bl X
1353-1078-872-
603-
310.
271,281-234-194- Conditioned medium from cells treated with 0 or I0" 4 M fumonisin B, was collected from days 0-4, nucleic acids were isolated and subjected to electrophoresis through 2% agarose gels impregnated with 0.5 |ig/ml ethidium bromide.
terminal differentiation and senescence. Some cells should begin to differentiate during the experiment. Chromatin condensation and fragmentation are consequences of the differentiation process and the resulting DNA strand breaks would be available for labeling by in situ end-labeling. However, the number of cells and the intensity of in situ endlabeling as a result of exposure to fumonisin B, greatly exceeds the labeling accountable for by the process of terminal differentiation as observed in the controls (Figure 7D-F) . Furthermore, the morphological differences between terminally differentiating and apoptotic keratinocytes allowed discrimination between these processes.
Fumonisin B t increases extracellular nucleosomal DNA fragments released from keratinocytes
Murine keratinocytes undergoing terminal differentiation activate an endogenous endonuclease that cleaves chromatin into nucleosome-sized fragments reminiscent of those observed in apoptotic lymphocytes (28) . Fragmented DNA released extracellularly from these cells is detected in the conditioned medium (28) . We examined the conditioned medium from NHKc treated with 10"" 4 M fumonisin B, for 0-4 days and noted maximal DNA fragmentation between days 1 and 2 of treatment ( Figure 8 ). However, DNA extracted from the cell pellets did not exhibit extensive chromatin fragmentation (data not presented). These results show that fumonisin B| induces DNA fragmentation in human keratinocytes consistent with apoptosis and that the nucleosomal chromatin fragments are released extracellularly.
Discussion
The principal effect of fumonisin B, on the various human cell types examined in this study was anti-proliferative, resulting from increased apoptotic cell death, as opposed to decreased cellular replication. Anti-proliferative effects of fumonisin B | have also been reported in a panel of rat hepatoma cell lines in culture (H4TG, H4-II-E, H4-II-E-C3, Fao, MH1C1, McA-RH777 and McA-RH8994), LLC-PK1 porcine kidney epithelial cells and MDCK canine kidney epithelial cells, with ICso values ranging between 2.5 and 50X10" 6 M fumonisin B, (33) (34) (35) . Qureshi and Hagler (36) reported significant cytotoxicity and morphological features consistent with apoptosis, such as nuclear fragmentation and membrane blebbing, in primary cultures of chicken peritoneal macrophages exposed to 2.8X 10" 6 M fumonisin B, for 2-A h. With the exception of Swiss 3T3 murine fibroblasts, fumonisin B, appears to inhibit the growth of both normal and transformed cells in culture.
The anti-proliferative effects of fumonisin B, could be explained either by decreased cell replication, which would be expected to decrease the fraction of S phase cells, or by increased cell death, through necrosis or apoptosis. NHKc were exposed to a growth inhibitory dose of fumonisin B : (i.e. 10~5 M) for 40 h and then subjected to cell cycle analysis using BrdU incorporation and propidium iodide counterstaining. Taking into account the average generation time for basal NHKc under the culture conditions used in this experiment (24-30 h), a 20-25% decrease in S phase cells would be necessary at 40 h in order to achieve the 50% decrease in final cell number observed in 5-6 day clonal growth assays if the anti-proliferative effects of fumonisin B| were due to a diminished capacity to traverse the cell cycle. We observed no change in the S phase population of fumonisin B|-treated NHKc nor did we observe arrest in GQ/GI or G 2 /M phases after fumonisin B, treatment of NHKc. Terminally differentiating NHKc are also characterized by accumulation in G o . Therefore, these data suggest that the rate of cell death must be increased to account for the decreased NHKc proliferation observed in response to fumonisin B| and are inconsistent with induction of NHKc terminal differentiation.
We report that fumonisin B| does not act as a mitogen in the normal and transformed human cells used in this study. Fumonisin B| consistently exhibited growth inhibitory effects in these cells at similar concentrations (IC50 values between 0.1 and 1.0xl0~5 M fumonisin B|). This observation suggests that fumonisin B1 perhaps affects a common target in each of these cell types. Ceramide synthase represents an obvious target candidate based on observations that fumonisin B| exposure results in accumulation of the sphingoid base substrates for that enzyme, sphinganine and sphingosine (7, 34, (37) (38) (39) (40) (41) (42) . Ceramide synthase catalyzes the formation of dihydroceramide or ceramide from sphinganine and sphingosine and dihydroceramide and ceramide levels have been shown to drop in fumonisin B|-treated cells (39) (40) (41) (42) (43) .
The processes of growth, terminal differentiation, senescence and apoptosis in NHKc have been well studied because of their significance in human dermatopathologies, such as carcinomas, papillomas, psoriasis, lichen planus, follicular keratosis (Darier's disease) and xeroderma pigmentosum (44, 45) . In fact, apoptosis and terminal differentiation share similar characteristics in keratinocytes. End stage, terminally differentiated keratinocytes observed in the cornified epidermal layer of skin are highly keratinized, enucleated squames enclosed by rigid, cornified cellular envelopes whose organelles have disintegrated. End stage apoptotic keratinocytes observed in vivo also exhibit chromatin and nuclear fragmentation and are enclosed by a cornified envelope. Terminally differentiating NHKc express transglutaminases I and III, as do apoptotic cells (45) (46) (47) (48) .
A significant characteristic shared by the processes of apoptosis and terminal differentiation in keratinocytes is the loss of clonogenicity when cells are replated. Keratinocytes treated with serum, high calcium concentrations (>1.5 mM) or activators of protein kinase C are induced to terminally differentiate (49) (50) (51) . Terminally differentiating NHKc and apoptotic cells lose their plating efficiency (45, 51) . In addition to expression of transglutaminase, other molecular changes associated with NHKc terminal differentiation include increased expression of keratin filament proteins, increased expression of involucrin and filaggrin and decreased expression of Bcl-2 and c-Myc proteins. The cell morphology changes from a cuboidal, basal cell type to the squamous type typical of the cornified epidermal epithelium. As expression of keratin tonofilaments and transglutaminase-catalyzed involucrin and loricrin cross-links increase, the ability of the cell to change shape decreases (45) . Apoptotic basal keratinocytes with fewer keratin tonofilaments are freer to change cell size and shape than apoptotic cells of the stratum granulosum, which are more thoroughly keratinized and resistant to morphological changes. Thus cytoplasmic and nuclear condensation, which results in shrinkage of most apoptotic cell types, will not necessarily be observed in all apoptotic NHKc, because the process of apoptosis can be initiated at any stage of NHKc differentiation from the basal cell layer through to the stratum spinosum and stratum granulosum. These facts preclude the simplistic application of FSC and SSC analyses by flow cytometry in our studies to discriminate unambiguously between viable, apoptotic, necrotic and terminally differentiated keratinocytes, because these parameters depend on cell size and granularity.
We have observed that NHKc exposed to growth inhibitory levels of fumonisin B] (>10~5 M fumonisin B|) contain DNA strand breaks in the absence of morphological changes. A significant fraction (3.62%) of untreated NHKc can be labeled positively in situ for DNA strand breaks. This is consistent with the consideration that NHKc primary cultures represent a heterogeneous mixture of cells in various stages of terminal differentiation.
We have noted that fragmented DNA accumulates in the conditioned medium of fumonisin B,-treated NHKc after 1-2 days exposure to fumonisin B,, prior to obvious changes in morphology. The clonogenicity of fumonisin B]-treated NHKc drops to 44.5% of control after 2 days exposure and to 0.3% of control after 4 days. However, dramatic changes in NHKc morphology, accompanied by changes in chromatin staining with acridine orange, in response to fumonisin B | do not occur until day 4 of exposure. Similarly, accumulation of non-viable NHKc (propidium iodide-positive, fluorescein-negative) occurs on day 4 of exposure. Electron microscopic examination of these sorted fumonisin B,-treated NHKc revealed that this population is composed of late stage apoptotic and necrotic cells.
The NHKc apoptotic process induced by fumonisin B] is then initially characterized by decreased clonogenicity, occurring between days 1 and 2 of exposure, which coincides with chromatin condensation and fragmentation and extracellular release of nucleosomal DNA fragments. Cellular esterase functions are retained, along with membrane integrity, presumably until the cell has lost most of its metabolic competency in the mid to later stages of NHKc apoptosis. After that point the cell is no longer capable of maintaining plasma membrane integrity or osmotic balance and these late stage apoptotic NHKc undergo swelling, culminating in secondary necrosis. These data demonstrate that fumonisin B,-induced apoptosis in NHKc requires days to progress fully to secondary necrosis. The relatively slow progress of this process could be due, in part, to a requirement for metabolic activity initially. The development of the internal apoptotic signal might involve the effects of ceramide synthase inhibition. In addition, the final process of secondary necrosis would not be expected to begin until energy-dependent membrane repair or osmotic balance are compromised.
Garmyn et al. (52) also noted partially detached, spherical NHKc in culture after irradiation with 32 mJ/cm 2 simulated sunlight. The irradiated cells were morphologically very similar to NHKc exposed to fumonisin B|. The irradiated spherical NHKc were highly variable in size and contained pyknotic nuclei and condensed cytoplasm, which is consistent with our observations of size variability in apoptotic NHKc. NHKc terminal differentiation is correlated with increased cell size, while apoptosis occurring in NHKc, at least in cells of the stratum basale, is correlated with cell shrinkage. The fact that NHKc are not known to be competent phagocytes is consistent with accumulation of these late stage apoptotic cells, which would be cleared in vivo by infiltrating neutrophils, macrophages or other phagocytic cells.
NHKc primary cultures in vitro are initially comprised of all three sub-populations of basal cells, but those with the least growth potential cannot propagate more than a few cells per colony. However, the progeny of the epidermal stem cell subpopulation constantly renew the populations of committed and transit amplifying cells. Interestingly, untreated control cells labeled positively for DNA strand breaks appear to occur in patches (not shown), consistent with initiation of the terminal differentiation process spreading from regions of mitotically active stem cell colony founders to more differentiated commit-ted cells arising from their progeny (45) . Furthermore, the occurrence of strongly labeled cells exhibiting morphological changes consistent with late stage NHKc apoptotic death appeared to occur somewhat more randomly, in clusters not well correlated with specific locations in NHKc colonies.
The panel of cell lines and tissues known to respond to fumonisin B, exposure through induction of apoptosis now includes normal and transformed human cells. One likely mechanism for the observed toxicological effects of fumonisin B, in various species in vivo may rest on the ability of fumonisin B, to stimulate apoptosis in a wide variety of cells. The fact that complex sphingolipids such as sphingomyelin represent a major portion of eukaryotic membranes suggests that ceramide synthase will be ubiquitously expressed in eukaryotes. Therefore, in the absence of specific mechanisms for fumonisin Bj resistance the potential for fumonisin B r mediated effects should be equally ubiquitous. We suggest that those cells not capable of excluding fumonisin B, should then be subject to sphingolipid perturbations. Those cells which are most responsive to altered levels of sphingolipid second messenger molecules will be stimulated, typically, to undergo apoptosis. The overall effects of this would be either loss of function for organ systems not under strict homeostatic control or hyperplasia to replace the cells lost by apoptosis. Marks etal. (53) demonstrated epidermal hyperplasia to replace cell loss due to increased keratinocyte cell death in NMRI mice treated epidermally with the non-TPA-type tumor promoter thapsigargin. Similarly, fumonisin B) does not stimulate protein kinase C activity and in fact, decreases it (54) . Therefore, the tumor promoting activity of fumonisin B] is of the non-TPA-type. Experiments are currently underway to characterize the molecular events by which apoptosis is induced by fumonisin B { .
